This is a preview of subscription content, log in via an institution to check access.
References
Public Health Service Task Force (2011) Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://AIDSinfo.nih.gov. Accessed 18 October 2011
Public Health Service Task Force (2011) Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. http://AIDSinfo.nih.gov. Accessed 18 October 2011
Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A (2009) Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 64:109–117. doi:10.1093/jac/dkp132
McKeown DA, Rosenvinge M, Donaghy S, Sharland M, Holt DW, Cormack I, Hay P, Sadiq ST (2010) High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 24(15):2416–2418. doi:10.1097/QAD. 0b013e32833d8a50
Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, Antoniou T, Loutfy MR (2010) Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 15:677–680. doi:10.3851/IMP1558
Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, Cauda R, Anzidei G, Cusato M, Regazzi M, Floridia M, Tamburrini E (2010) Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 65(9):2050–2052. doi:10.1093/jac/dkq264
Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 51(18):5843–5855. doi:10.1021/jm800245z
Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35:1657–63. doi:10.1124/dmd.107.016196
Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W (2005) Expression of the multidrug resistance P-glycoprotein (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27(6–7):602–609. doi:10.1016/j.placenta.2005.05.007
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Croci, L., Trezzi, M., Allegri, M.P. et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol 68, 1231–1232 (2012). https://doi.org/10.1007/s00228-012-1250-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-012-1250-5